Corrigendum

Corrigendum to “Low Body Mass Index Can Identify Majority of Osteoporotic Inflammatory Bowel Disease Patients Missed by Current Guidelines”

Ashish Atreja,1 Ashish Aggarwal,2 Angelo A. Licata,3 and Bret A. Lashner1

1Department of Gastroenterology, A-31, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
2Department of Internal Medicine, Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA
3Department of Endocrinology, Center for Space Medicine, Bone Metabolic Institute, Cleveland Clinic, Cleveland, OH 44195, USA

Correspondence should be addressed to Ashish Atreja; atrejaa@ccf.org

Received 11 May 2017; Accepted 22 May 2017; Published 14 August 2017

Copyright © 2017 Ashish Atreja et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Low Body Mass Index Can Identify Majority of Osteoporotic Inflammatory Bowel Disease Patients Missed by Current Guidelines” [1], there was an error regarding the FRAX* tool, which should be clarified as follows.

The article notes: “In fact, the WHO fracture risk predictor model (FRAX) based on data derived from nine cohorts from Europe, North America, Asia, and Australia includes low BMI as an important clinical predictor to predict 10-year probability of fracture [11].” However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX tool or its recommendations [2]. The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.

References
